Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Company Overview - Cogent Biosciences (NASDAQ: COGT) is a clinical-stage biotech company focused on genetically defined diseases, with its lead candidate Bezuclastinib [1] - Bezuclastinib is currently in 3 ongoing late-stage trials targeting AdvSM, non-AdvSM, and GIST [1] Clinical Trials - The company's success hinges on the outcomes of its 3 late-stage trials for Bezuclastinib [1] Author Background - The author, Myriam Hernandez Alvarez, holds multiple degrees including a Ph.D. in computer applications and collaborates professionally with Edgar Torres H [1]